During its policy committee meetings, PMC members debate and establish the Coalition's policy priorities and positions. These meetings frequently feature policy leaders, including representatives from the U.S. Food and Drug Administration (FDA), the Centers for Medicare & Medicaid Services (CMS), and Congressional staffers, as guest speakers.
For questions about PMC's policy committee meetings, please contact David Davenport, Manager, Public Policy & Secretary to the Board.
December 15, 2020
Assessing the Landscape for Advancing Personalized Medicine in 2021
Reps. Eric Swalwell (D-CA) and Scott Peters (D-CA) will join us during the next meeting of PMC's Public and Science Policy Committees on December 15 from 12:15 to 1:00 p.m. ET to discuss H.R. 4144: Ending the Diagnostic Odyssey Act and H.R. 4393: Advancing Access to Precision Medicine Act. Rep. Swalwell's Chief of Staff, Michael Reed, and Health Policy Advisor, Adeola Adesina, will attend the meeting alongside Rep. Peters' Chief of Staff, Daniel Zawitoski, to discuss the two bills proposing coverage of sequencing services for certain individuals, including the prospects for reintroduction of the bills in the next Congress and how PMC members can be helpful in ensuring that legislation in this area can best meet the needs of patients.
During the business meeting, PMC members will discuss our progress and direction in advocacy and evidence development, with reference to PMC's evolving research agenda and forthcoming Policy Agenda for 2021, President Trump's "most favored nations" executive order on reference pricing, and the sixth edition of PMC's signature document, The Personalized Medicine Report: Opportunity, Challenges, and the Future.
September 24, 2020
Advancing Genomic Testing and Patient Priorities for Personalized Medicine
During the business meeting, PMC discussed the insights from a new PMC report on genomic testing utilization and coverage in the United States, considered the priorities defined in its new patient-centered research agenda for personalized medicine, and began shaping the Coalition's agenda for 2021.
To kick off the meeting, PMC Manager of Public Policy David Davenport and Senior Vice President for Science Policy Daryl Pritchard, Ph.D., summarized the insights from Moving Beyond Population Averages: A Patient-Centered Research Agenda Advancing Personalized Medicine and Understanding Genomic Testing Utilization and Coverage in the US. Following their presentations, the policy committee considered next steps in advocacy and evidence development with reference to PMC's research program to understand and deliver the clinical and economic benefits of personalized medicine, President Donald Trump's "most favored nations" executive order on reference pricing, and PMC's 2021 planning process and related discussion questions.
June 29, 2020
Defining Priorities for the Field Against the Backdrop of COVID-19
During the business meeting, PMC members discussed their latest advocacy and evidence development activities to advance personalized medicine against the backdrop of the COVID-19 pandemic.
In addition to sharing their thoughts on how the COVID-19 pandemic will impact personalized medicine, updates were shared on responding to U.S. Reps Diana DeGette (D-CO) and Fred Upton (R-MI)'s 21st Century Cures 2.0 Concept Paper, advocating for improved reimbursement pathways for chimeric antigen receptor (CAR)T-cell therapies, and advancing PMC's research program and sponsorship opportunities supporting the study of the clinical and economic utility of personalized medicine in multiple disease states, including PMC's initiative to understand genomic testing utilization and coverage in the U.S.
May 7, 2020
Personalized Medicine in the Era of COVID-19
During the business meeting, PMC members discussed their latest advocacy and evidence development activities to advance personalized medicine against the backdrop of the COVID-19 pandemic. Given the exigencies of the moment, the meeting was held virtually and shortened to one hour.
In addition to sharing thoughts on how the COVID-19 pandemic would impact personalized medicine, we discussed our efforts to recruit additional members for the Congressional Personalized Medicine Caucus, advocate for improved reimbursement pathways for chimeric antigen receptor (CAR) T-cell therapy and advance PMC's Research Program Studying the Clinical and Economic Utility of Personalized Medicine in Multiple Disease States.
Prior to the meeting, we encouraged review of the following summary from February's month's meeting - Action Items: A Meeting of PMC's Public and Science Policy Committees (February 27, 2020).
February 27, 2020
featuring staff from the offices of the Congressional co-chairs of the new bicameral, bipartisan Personalized Medicine Caucus
Staff from the offices of the Congressional co-chairs of the new bicameral, bipartisan Personalized Medicine Caucus joined the meeting of PMC's Public and Science Policy Committees on February 27 to discuss their respective members' interests in personalized medicine and the caucus' introductory briefing on the benefits of earlier detection, targeted treatment, and improved prevention strategies, which was scheduled for February 26. Our featured speakers during the committee meeting included Adeola Adesina, Legislative Assistant, Office of Rep. Eric Swalwell (CA-15) and Catherine Lenz, Legislative Assistant, Office of Rep. Tom Emmer (MN-06).
During a business meeting following the conversation with Adesina and Lenz, PMC members discussed the latest policy developments impacting personalized medicine including, recruiting members of Congress to join the Congressional Personalized Medicine Caucus, PMC’s ongoing and proposed evidence development projects and sponsorship opportunities, PMC’s activities in pharmacogenomics, the Verifying Accurate Leading-edge IVCT Development (VALID) Act and H.R. 5741, the Strengthening Innovation in Medicare and Medicaid Act.